D. Raffaele, H. Steen, and L. W. , General mechanisms of coagulation and targets of anticoagulants, Thrombosis and Haemostasis, vol.109, pp.569-579, 2013.

G. Nowak, New anticoagulants for secondary haemostasis : anti IIa inhibitors, Hamostaeologie, pp.256-265, 2009.

H. Levesque and L. , L'histoire des traitements anticoagulants, La Revue de M??decine Interne, vol.25, pp.315-322, 2004.
DOI : 10.1016/S0248-8663(04)80002-X

C. Ruff, R. Giulgliano, and E. Braunwald, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, The Lancet, vol.383, issue.9921, pp.955-62
DOI : 10.1016/S0140-6736(13)62343-0

URL : https://hal.archives-ouvertes.fr/hal-00935589

N. Dumarcet, F. Goebel, and P. Cavalié, Les anticoagulants en France en 2012 : Etat des lieux et surveillance, Agence National des sécurité du médicament et produits de santé, 2012.

B. Limone, W. Baker, and J. Kluger, Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models, PLoS ONE, vol.2, issue.4, 2013.
DOI : 10.1371/journal.pone.0062183.s007

V. Schéele, B. Fernandez, M. Hogue, and S. , Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US, Annals of Pharmacotherapy, vol.19, issue.2, pp.671-85, 2013.
DOI : 10.1016/j.jacc.2012.03.019

G. Callejo, F. , B. Martínez, C. , C. González et al., Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant, Acta Otorrinolaringol Esp, vol.14, pp.1-6519

D. Nell, Extension d'indication pour le fondaparinux, AMC pratique, p.28, 2008.

H. Henri, V. Versteeg, J. W. Heemskerk, M. Marcel, and L. , New fundamentals in hemostasis, Physiol Rev, vol.93, pp.327-358, 2013.

A. Masrar, A. Jeaidi, and R. Seddik, La coagulation sanguine : vers une vue nouvelle, Journal de Biologie Médicale, p.2012

?. Selimovi?, S. Imamovi?, and F. Ljuca, Changes in activated partial thromboplastin time and international normalised ratio after on-pump and off-pump surgical revascularization of the heart, Bosn J Basic Med Sci, vol.14, issue.2, pp.70-74, 2014.

T. Revel and K. Doghmi, Physiologie de l'hémostase, EMC ; Stomatologie, pp.22-31, 2004.

R. Ellis and D. Kaiser, The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients, Vascular Health and Risk Management, pp.341-352, 2013.

A. Sternotte, J. Douwxfils, and B. Chatelain, Dabigatran dans la fibrillation auriculaire : études cliniques, intérêts et limites, Journal de Pharmacie de Belgique, p.2012

C. Lee and A. E. , Direct thrombin inhibitors, British Journal of Clinical Pharmacology, vol.103, issue.1, 2011.
DOI : 10.1111/j.1365-2125.2011.03916.x

E. Perzborn, S. Roehrig, and A. Straub, Rivaroxaban: A New Oral Factor Xa Inhibitor, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.3, pp.376-381, 2010.
DOI : 10.1161/ATVBAHA.110.202978

I. Elalamy, Héparine : structure, propriétés pharmacologiques et activités, EMC ; Hématologie, pp.13-022, 2010.

V. Simonnet, J. Cambus, and P. Léger, Antivitamines K : utilisation pratique EMC ; Hématologie, 13-022-D-50, p.10, 2003.

W. Mueck, S. Stephan, and J. Stampfuss, Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring, Thrombosis Journal, vol.11, issue.1, 2013.
DOI : 10.1177/1076029612441859

J. Emmanuel, . Favaloro, and G. Lippi, The new oral anticoagulants and the future of haemostasis laboratory testing, Biochemia Médica, vol.22, issue.3, pp.329-370, 2012.

M. Flisinkski, H. Windyga, and E. Stefanska, Acquired hemophilia: a case report, Pol Arch Med Wewn, vol.118, issue.4, pp.228-261, 2008.

M. Vaubourdolle, Physiologie de l'hémostase primaire et de la coagulation, Biochimie et Hématologie tome 2, 3ième édition, pp.839-848, 2013.

D. Raimondo and A. Tuttolomondo, Antivitamin K Drugs in Stroke Prevention, Current Vascular Pharmacology, vol.11, issue.6, pp.817-840, 2013.
DOI : 10.2174/157016111106140128113404

U. Bal, A. Aydinalp, and K. Yilmaz, The effects is a low INR on thromboembolic, J Cardiothorac Surg, vol.79, issue.79, p.2014

D. Keeling, T. Bagli, and T. Campbell, Guidelines on oral anticoagulation with warfarin - fourth edition, British Journal of Haematology, vol.335, issue.Suppl. 2, 2011.
DOI : 10.1111/j.1365-2141.2011.08753.x

J. Rem, F. Duckert, and R. Fridrich, Subcutaneous small heparin doses for the prevention of thrombosis in general surgery and urology, Schweiz Med Wochenschr, vol.28105, issue.26, pp.827-862, 1975.

W. Mueck, S. Schwers, and J. Stampfuss, Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring, Thrombosis Journal, vol.11, issue.1, 2013.
DOI : 10.1177/1076029612441859

J. Daubert and L. Fauchier, Fibrillation atriale et risque thrombo-embolique, la revue du praticien médecine générale, pp.624-629, 2012.

C. Fenger-eriksen, A. Munster, and E. Grove, New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications, Acta Anaesthesiologica Scandinavica, vol.127, issue.6, pp.651-660
DOI : 10.1111/aas.12319

T. Helin, A. Pakkanen, and R. Lassila, Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability between Coagulation Laboratories, Clinical Chemistry, vol.59, issue.5, pp.807-821, 2013.
DOI : 10.1373/clinchem.2012.198788

D. Brieger and J. Curnow, Anticoagulation : a GP primer on the new oral anticoagulants, Focus Cardiology, vol.43, issue.5, pp.254-263, 2014.

T. Lindahl, F. Baghaei, I. Fagerberg, and B. , Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays, Thrombosis and Haemostasis, vol.105, issue.2, pp.371-379, 2011.
DOI : 10.1160/TH10-06-0342

. Love, C. Ferrell, and W. Chandler, Monitoring direct thrombin inhibitors with a plasma diluted thrombin time, Thrombosis and Haemostasis, vol.98, issue.1, pp.234-276, 2007.
DOI : 10.1160/TH06-10-0607

V. Siguret, I. Gouin-thibault, and P. Sie, Dabigatran etexilate et examens de biologie médicale, Agence National des sécurité du médicament et produits de santé, 2013.

W. Dager, R. Gosselin, and S. Kitchen, Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study, Annals of Pharmacotherapy, vol.142, issue.1, pp.1627-1663
DOI : 10.1345/aph.1R179

J. Van-ryn, J. Stangier, and S. Haertter, Dabigatran etexilate ??? a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity, Thrombosis and Haemostasis, vol.103, issue.6, pp.1116-1143, 2010.
DOI : 10.1160/TH09-11-0758

I. Gouin-thibault and P. Sié, Rivaroxaban et tests de biologie médicale, Agence National des sécurité du médicament et produits de santé, p.2012

A. Hillarp, K. Gustafsson, and L. Faxälv, Effects of the oral, direct factor Xa inhibitor apibaxan on routine coagulation assays and anti-Xa assays, J Thromb Haemost, p.2014

M. Samama, G. Contant, and E. Spiro, Laboratory assessment of rivaroxaban: a review, Thrombosis Journal, vol.11, issue.1, 2013.
DOI : 10.1186/1477-9560-11-11

E. Lindhoff-last, M. Samama, and T. Ortel, Assays for Measuring Rivaroxaban: Their Suitability and Limitations, Therapeutic Drug Monitoring, vol.32, issue.6, pp.673-682, 2010.
DOI : 10.1097/FTD.0b013e3181f2f264

I. Gouin-thibault, C. Flaujac, and X. Delavenne, Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays, Thrombosis and Haemostasis, vol.111, issue.2, pp.240-248, 2014.
DOI : 10.1160/TH13-06-0470

D. Siegal and M. Crowther, Acute management of bleeding in patients on novel oral anticoagulants, European Heart Journal, vol.34, issue.7, pp.489-498, 2012.
DOI : 10.1093/eurheartj/ehs408

P. Chin, D. Wright, and D. Patterson, A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time, British Journal of Clinical Pharmacology, vol.32, issue.Suppl. 1, p.2014
DOI : 10.1111/bcp.12364

J. Douxfils, F. Mullier, and S. Robert, Impact of dabigatran on a large panel of routine or specific coagulation assays, Thrombosis and Haemostasis, vol.107, issue.5, pp.985-97, 2012.
DOI : 10.1160/TH11-11-0804

H. Mani and E. Lindhoff-last, New oral anticoagulants in patients with non valvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness, Drug Des Devel Ther, pp.789-798, 2014.

M. Samama, J. Conard, and M. Horellou, Deux nouveaux anticoagulants disponibles en 2010???????Dabigatran Etexilate et Rivaroxaban: progr??s attendus???????probl??mes pos??s, Annales Pharmaceutiques Fran??aises, vol.68, issue.6, pp.359-69, 2010.
DOI : 10.1016/j.pharma.2010.08.001

M. Samamaa, J. Conard, and C. Flaujac, Pharmacologic heterogeneity of new anticoagulants, J Mal Vasc, vol.1, issue.11, pp.10-570002, 2011.

M. Samama, G. Contant, and S. , Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls, Thrombosis and Haemostasis, vol.107, issue.2, pp.379-87, 2012.
DOI : 10.1160/TH11-06-0391

Y. Cui, Y. Song, and J. Wang, Single and multiple dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects, Clin Pharmacol, vol.5, pp.177-84, 2013.

R. Gosselin, E. Hawes, and S. Moll, Performance of Various Laboratory Assays in the Measurement of Dabigatran in Patients Receiving Therapeutic Doses: A Prospective Study Based on Peak and Trough Plasma Levels, American Journal of Clinical Pathology, vol.141, issue.2, pp.262-269, 2014.
DOI : 10.1309/AJCPRNUMI4PVSJ7Q

E. Favaloro and G. Lippi, The new oral anticoagulants and the future of haemostasis laboratory testing, Biochemia Medica, vol.22, issue.3, pp.329-370, 2012.
DOI : 10.11613/BM.2012.035

A. Bauer, Pros and cons of new oral anticoagulants, Hematology, vol.2013, issue.1, 2013.
DOI : 10.1182/asheducation-2013.1.464

H. Fakhri, S. Janket, and J. E. , Tutorial in Oral antithrombotic therapy: Biology and dental implications, Medicina Oral Patolog??a Oral y Cirugia Bucal, vol.18, issue.3, pp.461-72, 2013.
DOI : 10.4317/medoral.19140

C. Davis, C. Robertson, and S. Shivakumar, Implications of Dabigatran, a Direct Thrombin Inhibitor, for Oral Surgery Practice, J Can Dent Assoc, vol.79, p.74, 2013.

J. Dminon and P. Borgons, Usage des nouvelles molécules anticoagulantes dans la pratique quotidienne, Journée médicale du CHR de la Citadelle, pp.10-2012

K. Romond, C. Miller, and R. Henry, Dental management considerations for a patient taking dabigatran etexilate: a case report, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol.116, issue.3, 2013.
DOI : 10.1016/j.oooo.2013.05.001

S. Sindet-pedersen, G. Ramström, and S. Bernvil, Hemostatic Effect of Tranexamic Acid Mouthwash in Anticoagulant-Treated Patients Undergoing Oral Surgery, New England Journal of Medicine, vol.320, issue.13, pp.840-843, 1989.
DOI : 10.1056/NEJM198903303201305

C. Ward, G. Conner, and G. Donnan, Practical management of patients on apixaban: a consensus guide, Thrombosis Journal, vol.11, issue.1, pp.27-37, 2013.
DOI : 10.2174/138161210793563338

B. Heindl and M. Spannagl, New oral anticoagulants, Der Anaesthesist, vol.122, issue.12, pp.1252-1257, 2009.
DOI : 10.1007/s00101-009-1623-z

S. Lévy, Newer clinically available antithrombotics and their antidotes, Journal of Interventional Cardiac Electrophysiology, vol.128, issue.36, 2014.
DOI : 10.1007/s10840-014-9910-2

G. Breuer, D. Weiss, and J. Ringwald, ???New??? direct oral anticoagulants in the perioperative setting, Current Opinion in Anaesthesiology, vol.27, issue.4, pp.409-428
DOI : 10.1097/ACO.0000000000000100

G. Moreno, A. Aguilar-salvatierra, and M. Martín-piedra, Dabigatran and rivaroxaban, new oral anticoagulants. new approaches in dentistry, J Clin Exp Dent, vol.2, issue.1, pp.1-5, 2010.

K. Babilonia and T. Trujillo, The role of prothrombin complex concentrates in reversal of target specific anticoagulants, Thrombosis Journal, vol.12, issue.1, 2014.
DOI : 10.1038/nm.3102

M. Makris, J. J. Van-veen, and R. Campbell, Guideline on the management of bleeding in patients on antithrombotic agents, British Journal of Haematology, vol.18, issue.Suppl. 2, pp.35-46
DOI : 10.1111/bjh.12107

G. Pernoda, P. Albaladejob, and A. Godierc, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis, Archives of Cardiovascular Disease, pp.382-393

E. Eerenberg, P. Kamphuisen, and M. Sijpkens, Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate, Circulation, issue.14, p.1241573, 2011.

C. Samama, G. Pernod, and P. Albaladejo, Gestion péri-opératoire des nouveaux anticoagulants oraux, La presse médicale, p.2014
DOI : 10.1016/j.jeurea.2014.10.005

G. Pernod, Prise en charge des complications h??morragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d???int??r??t en H??mostase P??riop??ratoire (GIHP) - mars 2013, Annales Fran??aises d'Anesth??sie et de R??animation, vol.32, issue.10, 2013.
DOI : 10.1016/j.annfar.2013.04.016

P. Sié, Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct, Ann Fr Anesth Reanim, 2011.

A. Rose and D. Pharm, Periprocedural Anticoagulation ? Adult ? Inpatient and Ambulatory ? Clinical Practice Guideline, p.2013